InsidersTradesSigma
Total declarations
Companies
▲ Purchases (2 ops.)
▼ Sales (0 ops.)
Insider track record
ExecutiveDisclosed buys
2
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Discover the detailed record of transactions filed by Breitmeyer James B, Director. Insider active across 3 companies, notably Vaxart, Inc.. Cumulatively, 10 disclosures have been published. Breakdown: 2 buys · 0 sell. Total volume traded: €64k. Activity tracked since 3 January 2022. The latest transaction was filed on 16 July 2026 (Attribution). Regulator: SEC (Form 4). All data is free.
Companies and markets linked to Breitmeyer James B
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations10 total
8,315 shares0Common StockSEC:0001437749-26-023810:0
78,800 shares0Common StockSEC:0001437749-26-014528:0
50,955 shares@ US$0.496113.9% of flowCommon StockSEC:0001209191-24-000970:0
47,992 shares@ US$0.369.5% of flowCommon StockSEC:0001209191-23-041319:0
100,000 shares@ US$0.2915.7% of flowCommon StockSEC:0001209191-23-024390:0
Canonical exit: 12 Jul 2023 (T+90)
27,793 shares@ US$1.0215.9% of flowCommon StockSEC:0001209191-23-002033:0
185,625 shares0Common StockSEC:0001209191-22-043735:0
1,250 sharesCommon StockSEC:0000899243-22-010312:0
25,000 shares@ US$1.683250.0% of flowCommon StockSEC:0001209191-22-005556:0
Canonical exit: 27 Apr 2022 (T+90)
128,557 shares0Common StockSEC:0001209191-22-001974:0
10 of 10 declarations
About Breitmeyer James B
James B. Breitmeyer is the Chief Executive Officer of Vaxart, Inc., Oncternal Therapeutics, Inc., and ZOGENIX, INC. He leads these companies with a focus on innovation and the development of new treatments. His leadership is essential for the growth of these firms.
